Kyowa Kirin Co Ltd
TSE:4151
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 268
3 325
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Kyowa Kirin Co Ltd
Kyowa Kirin Co Ltd
Net Income (Common)
Kyowa Kirin Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kyowa Kirin Co Ltd
TSE:4151
|
Net Income (Common)
¥83.5B
|
CAGR 3-Years
25%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Net Income (Common)
¥290B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
28%
|
CAGR 10-Years
12%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Net Income (Common)
¥250.4B
|
CAGR 3-Years
42%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Net Income (Common)
¥151.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-1%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Net Income (Common)
¥387B
|
CAGR 3-Years
15%
|
CAGR 5-Years
23%
|
CAGR 10-Years
22%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Net Income (Common)
¥54.6B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-6%
|
|
Kyowa Kirin Co Ltd
Glance View
Kyowa Kirin Co., Ltd. is a global biopharmaceutical company rooted in Japan, well-regarded for its commitment to developing innovative therapies that address unmet medical needs. Founded in 1949, the company has evolved significantly over the decades, transitioning from a traditional pharmaceutical manufacturer to a cutting-edge biotechnology leader. Kyowa Kirin harnesses its expertise in research and development to focus on critical areas such as oncology, immunology, and nephrology, leveraging proprietary technologies to create unique biologics that enhance patient outcomes. With a diverse pipeline of products and a strong emphasis on collaboration, both within Japan and with international partners, the company positions itself as a key player in the rapidly evolving biopharmaceutical landscape. For investors, Kyowa Kirin represents not just a robust financial opportunity but also the embodiment of long-term value creation, reflecting the investment principles of renowned thinkers like Warren Buffett and Charlie Munger. The company maintains a sound financial profile, characterized by steady revenue growth, a solid balance sheet, and a commitment to shareholder returns through dividends and strategic reinvestments. As the global demand for innovative healthcare solutions escalates, Kyowa Kirin's ongoing commitment to R&D, coupled with its strategic alliances and acquisitions, positions it well for sustainable growth and resilience in the face of market fluctuations. Investors seeking to capitalize on the burgeoning biopharmaceutical sector should consider Kyowa Kirin as a potential long-term investment opportunity in a company poised to make a meaningful impact on global health.
See Also
What is Kyowa Kirin Co Ltd's Net Income (Common)?
Net Income (Common)
83.5B
JPY
Based on the financial report for Sep 30, 2024, Kyowa Kirin Co Ltd's Net Income (Common) amounts to 83.5B JPY.
What is Kyowa Kirin Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
16%
Over the last year, the Net Income (Common) growth was 44%. The average annual Net Income (Common) growth rates for Kyowa Kirin Co Ltd have been 25% over the past three years , 6% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet
